A noteworthy prognostic marker in extensive small cell lung cancer: lymphocyte/C-reactive protein ratio

Figen Öztürk Ergür; Ayperi Öztürk; Melahat Uzel Şener; Zeynep Tilbe Saymaz; Nihal Mutlu

Makale detayları

A noteworthy prognostic marker in extensive small cell lung cancer: lymphocyte/C-reactive protein ratio

Yazarlar:

Figen Öztürk Ergür | Ayperi Öztürk | Melahat Uzel Şener | Zeynep Tilbe Saymaz | Nihal Mutlu

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Göğüs Hastalıkları

Dergi:

Journal of Medicine and Palliative Care Vol.4 Issue 4, pp.341-344

Belge Tipi:

Makale

Yayın Tarihi:

8/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001297613

pISSN:

2717-7505

Anahtar kelimeler:

Özet:

 Aims: We aimed to investigate the pre-treatment prognostic significance of lymphocyteC-Reactive protein ratio LCR, one of the inflammatory factors, in patients with extensive-stage small cell lung cancer SCLC. Methods: Medical records of 514 patients who were diagnosed with extensive-stage SCLC between 2010 and 2020 were examined retrospectively. LCR was calculated using the blood test results prior to chemotherapy. Results: The mean survival time for extensive-stage SCLC is 6 months 5.3-6.7. A statistically significant difference exists between limited and extensive stages in terms of median overall survival OS p0.001. The baseline LCR value of the patients was determined as 0.5 0-311. LCR exerts a statistically significant effect on overall survival 0.025. Every 1 unit increase in LCR reduces death by 1.004 times. Conclusion: Pre-treatment LCR value can be used as an independent prognostic parameter associated with mean survival in extensive SCLC.

 Aims: We aimed to investigate the pre-treatment prognostic significance of lymphocyteC-Reactive protein ratio LCR, one of the inflammatory factors, in patients with extensive-stage small cell lung cancer SCLC. Methods: Medical records of 514 patients who were diagnosed with extensive-stage SCLC between 2010 and 2020 were examined retrospectively. LCR was calculated using the blood test results prior to chemotherapy. Results: The mean survival time for extensive-stage SCLC is 6 months 5.3-6.7. A statistically significant difference exists between limited and extensive stages in terms of median overall survival OS p0.001. The baseline LCR value of the patients was determined as 0.5 0-311. LCR exerts a statistically significant effect on overall survival 0.025. Every 1 unit increase in LCR reduces death by 1.004 times. Conclusion: Pre-treatment LCR value can be used as an independent prognostic parameter associated with mean survival in extensive SCLC.

 Aims: We aimed to investigate the pre-treatment prognostic significance of lymphocyteC-Reactive protein ratio LCR, one of the inflammatory factors, in patients with extensive-stage small cell lung cancer SCLC. Methods: Medical records of 514 patients who were diagnosed with extensive-stage SCLC between 2010 and 2020 were examined retrospectively. LCR was calculated using the blood test results prior to chemotherapy. Results: The mean survival time for extensive-stage SCLC is 6 months 5.3-6.7. A statistically significant difference exists between limited and extensive stages in terms of median overall survival OS p0.001. The baseline LCR value of the patients was determined as 0.5 0-311. LCR exerts a statistically significant effect on overall survival 0.025. Every 1 unit increase in LCR reduces death by 1.004 times. Conclusion: Pre-treatment LCR value can be used as an independent prognostic parameter associated with mean survival in extensive SCLC.

 Amaç: Yaygın evre küçük hücreli akciğer kanseri KHAK hastalarında inflamatuar faktörlerden lenfositC-Reaktif protein oranının LCR tedavi öncesi prognostik önemini araştırmayı amaçladık. Araçlar ve Yöntem: Retrospektif olarak 2010-2020 tarihleri arasında KHAK tanısı almış ve yaygın evrede olan 514 hastanın tıbbi kayıtları incelendi. Kemoterapi öncesi alınan kan tetkiklerinden LCR hesaplandı. Bulgular: Yaygın evre KHAKnin ortalama sağkalım süresi 6 aydır 5,3-6,7. Sınırlı ve yaygın hastalık arasında medyan genel sağkalım OS açısından istatistiksel anlamlı farklılık vardır p0.001. Hastaların başlangıç LCR değeri 0,5 0-311 olarak saptandı. LCRnin genel sağkalım üzerinde istatistiksel anlamlı etkisi vardır 0,025. LCRdeki 1 birimlik artış ölümü 1,004 kat azaltmaktadır Sonuç: Tedavi öncesi LCR, yaygın evre KHAKde ortalama sağkalımı gösteren bağımsız bir prognostik parametre olarak kullanılabilir.

Makale detayları

A noteworthy prognostic marker in extensive small cell lung cancer: lymphocyte/C-reactive protein ratio

Yazarlar:

Figen Öztürk Ergür | Ayperi Öztürk | Melahat Uzel Şener | Zeynep Tilbe Saymaz | Nihal Mutlu

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Göğüs Hastalıkları

Dergi:

Journal of Medicine and Palliative Care Vol.4 Issue 4, pp.341-344

Belge Tipi:

Makale

Yayın Tarihi:

8/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001297613

pISSN:

2717-7505

small cell lung cancer

lymphocyte/CRP ratio

prognostic factor

survivalküçük hücreli akciğer kanseri

lenfosit/CRP oranı

prognostik faktör

sağkalım

Sayı

Makale detayları

Yazarlar: Figen Öztürk Ergür | Ayperi Öztürk | Melahat Uzel Şener | Zeynep Tilbe Saymaz | Nihal Mutlu

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Göğüs Hastalıkları

Dergi: Journal of Medicine and Palliative Care Vol.4 Issue 4, pp.341-344

Belge Tipi: Makale

Yayın Tarihi: 8/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001297613

pISSN: 2717-7505

Sayı

Yazarlar:

Figen Öztürk Ergür | Ayperi Öztürk | Melahat Uzel Şener | Zeynep Tilbe Saymaz | Nihal Mutlu

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Göğüs Hastalıkları

Dergi:

Journal of Medicine and Palliative Care Vol.4 Issue 4, pp.341-344

Belge Tipi:

Makale

Yayın Tarihi:

8/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001297613

pISSN:

2717-7505